NorthStar Medical Radioisotopes will unveil the commercial model of its RadioGenix isotope separation system during three events on March 27 and March 28 in San Diego.
NorthStar is developing RadioGenix to create a U.S.-based supply of technetium-99m (Tc-99m). RadioGenix will produce high-specific-activity Tc-99m from low-specific-activity molybdenum-99 (Mo-99). RadioGenix is currently under review at the U.S. Food and Drug Administration (FDA).
NorthStar has two proprietary processes for producing Mo-99 without the use of highly enriched uranium (HEU). The system automates the onsite isotope separation process and includes safety features such as periodic onsite sterilization of fluid pathways, disposable sterility filters, and an automated filter integrity test prior to each elution.
